Trends in Molecular Medicine
Reviewα-1-Antitrypsin deficiency: clinical variability, assessment, and treatment
Section snippets
Fifty years of exploring the implications of α-1-antitrypsin deficiency
The original observation of a missing α1 protein based on paper electrophoresis of blood samples resulted in the first description of the clinical features of α-1-antitrypsin-deficient (AATD) subjects [1]. The subsequent 20–25 years consolidated an association of basal panacinar emphysema (see Glossary) with AATD, the identification of neutrophil elastase (NE) as its cognate proteinase with the ability to cause emphysema in animal models [2], and the logical development of α-1-antitrypsin (AAT)
α-1-Antitrypsin
AAT is a 52-kDa glycoprotein predominantly synthesised in hepatocytes from two alleles located on chromosome 14, although a small amount of protein is also made by monocytes/macrophages and airway epithelial cells that may have some local implications in the lung. AATD is the result of any of a variety of abnormalities in the AAT gene, including single point mutations, insertions and deletions, and even gene deletion. The majority of these variations have been covered in other reviews (e.g., [3]
Clinical variation
The initial patients described were young smokers with early onset basal panacinar emphysema. This has remained the ‘classical’ clinical phenotype and led to a testing policy confined to young COPD patients with a dominance of basal emphysema rather than the apical centrilobular emphysema of patients with COPD and normal AAT. Selective testing thus reinforced this as the clinical phenotype. However, significant variations in the ‘classical’ clinical phenotype have now become recognised (Figure 1
Other conditions
The other major morbidity in AATD due to homozygosity of the common Z variant gene relates to the liver. The Z gene variant protein product polymerises in the hepatocyte and accumulates within the endoplasmic reticulum [3]. This accumulated protein produces the classic Periodic acid–Schiff (PAS) positive inclusion bodies seen histologically [5]. The protein which accumulates in the hepatocyte enters the physiological degradation pathway; however, this is overloaded, and the end result is tissue
Epigenetics and genetic modifiers
Data suggest that although AATD predisposes to several clinical conditions the outcome is highly variable, indicating that other genetic or environmental factors may play a role (Table 1). Epigenetics refers to changes in the switching on/off of gene expression by factors other than DNA sequence; this might include environmental or lifestyle factors. Methylation is probably the best studied form of epigenetic change, in terms of predisposition to disease. DNA methylation in individuals with
Augmentation therapy
The susceptibility of AATD patients to the development of emphysema and the ability of neutrophil serine proteinases to produce many of the features of lung disease in experimental animals suggested cause and effect 2, 6, 7. For this reason, the logic of replenishing plasma (and hence lung) AAT was both sensible and subsequently shown to be feasible [62]. The infused half-life of AAT suggested that a reasonable regimen would be weekly infusions to restore AAT protection. However, it was
Biomarkers
Although lung physiology and radiological density are, by definition, biomarkers of lung damage in AATD, the term is commonly used in the context of a biochemical marker or relevant metabolite of the disease process or activity. Identification of biomarkers has enormous potential in the management of chronic lung diseases in general and, specifically, AATD. Markers specific for the presence and extent of the tissue damage leading to progressive lung and liver disease would enable clinicians to
Gene therapy
The classical form of gene therapy inserts normal genes into cells of patients with a genetic mutation. Studies of AAT gene therapy in animals have used retroviral [91], adenoviral 92, 93, 94, 95, 96, adeno-associated viral 97, 98, 99, and liposomal 100, 101 vectors to transfect cells. Recombinant adeno-associated viral vectors (rAAVs) containing the AAT gene have proven capable of achieving higher therapeutic levels of AAT 97, 98, and were less likely to induce an inflammatory response than
Concluding remarks
Although much has been learnt about AATD over the decades, and augmentation therapy has become widely available, much remains unknown. The true natural history of the condition in smokers and never smokers has yet to be determined, and may help explain why some individuals are particularly susceptible to the development of lung disease, fulminant hepatic failure, panniculitis, and Wegener's granulomatosis, whereas others are not. In addition, the reasons for and variations in the type and
Disclaimer statement
Professor R.A. Stockley has served on advisory boards for Grifols, Kamada, CSL Behring, and Baxter and has received fees for lecturing for Grifols and non-commercial grant funding from Grifols.
Glossary
- α-1-Antitrypsin deficiency (AATD)
- low circulating levels of α-1-antitrypsin.
- Apical centrilobular emphysema
- typical pattern of emphysema seen in COPD unrelated to AATD, where emphysema occurs in the upper zones and is most marked in the centre of pulmonary lobules.
- Asthma
- a condition in which intermittent airflow obstruction due to bronchospasm occurs; hallmarks include bronchodilator responsiveness (an increase in FEV1 of over 400 ml, or 12% of baseline value) and variability of peak expiratory flow
References (121)
Molecular basis of α-1 antitrypsin deficiency
Am. J. Med.
(1988)- et al.
Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from α-1-antitrypsin deficiency
Chest
(2007) Age related development of respiratory abnormalities in non-index α1 antitrypsin deficient studies
Respir. Med.
(2013)Lung function in 30-year-old α-1-antitrypsin-deficient individuals
Respir. Med.
(2009)- et al.
Bronchiectasis in patients with α1-antitrypsin deficiency. A rare occurrence?
Chest
(1993) Distribution of α(1)-antitrypsin alleles in patients with bronchiectasis
Chest
(2000)The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in α1-antitrypsin deficiency (PiZ)
Chest
(2002)Effect of expectoration on inflammation in induced sputum in α-1-antitrypsin deficiency
Respir. Med.
(2006)- et al.
Reported and unreported exacerbations of COPD: analysis by diary cards
Chest
(2008) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data
Chest
(2000)
The liver in adolescents with α1-antitrypsin deficiency
Hepatology
Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency
Clin. Gastroenterol. Hepatol.
A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis
Clin. Immunol.
α(1)-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts
Chest
Integration of genetic and genomic techniques identifies IREB2 as a COPD susceptibility gene
Am. J. Hum. Genet.
Longitudinal follow-up of patients with α(1)-protease inhibitor deficiency before and during therapy with IV α(1)-protease inhibitor
Chest
Biosynthesis of α1-proteinase inhibitor by human lung-derived epithelial cells
J. Biol. Chem.
Polymers of Z α1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo
Am. J. Pathol.
Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population
Atherosclerosis
Therapeutic serum concentrations of human α-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes
Hepatology
Expression of human α1-antitrypsin in mouse after in vivo gene transfer to hepatocytes by small liposomes
Biochem. Biophys. Res. Commun.
The electrophorectic α1-globulin pattern of serum in α1-antitrypsin deficiency
Scand. J. Clin. Lab. Invest.
The induction of pulmonary emphysema with human leukocyte elastase
Am. Rev. Respir. Dis.
Z-type α1-antitrypsin is less competent than M1-type α-1-antitrypsin as an inhibitor of neutrophil elastase
J. Clin. Invest.
The mechanism of Z α1-antitrypsin accumulation in the liver
Nature
Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters
J. Clin. Invest.
Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with in vitro observations on elastolysis by these enzymes
Am. Rev. Respir. Dis.
Induction of emphysema in hamsters by intratracheal instillation of cathepsin B
Am. Rev. Respir. Dis.
Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase
Proc. Natl. Acad. Sci. U.S.A.
α1-Antitrypsin suppresses TNF-α and MMP-12 production by cigarette smoke-stimulated macrophages
Am. J. Respir. Cell Mol. Biol.
Studies in α1-antitrypsin deficiency
Acta Med. Scand. Suppl.
Phenotypic differences in α1 antitrypsin deficient sibling pairs may relate to genetic variation
COPD
Pattern of emphysema distribution in α-1-antitrypsin deficiency influences lung function impairment
Am. J. Respir. Crit. Care Med.
Pathological findings in α1-antitrypsin deficiency
Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study augmentation therapy in α-1-antitrypsin deficiency
Respir. Res.
Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting
Bull. World Health Organ.
Prevalence and impact of bronchiectasis in α1-antitrypsin deficiency
Am. J. Respir. Crit. Care Med.
Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care
Thorax
Longitudinal changes in physiological, radiological and health status measurements in α1-antitrypsin deficiency and factors associated with decline
Am. J. Respir. Crit. Care Med.
Rate of progression of lung function impairment in α-1-antitrypsin deficiency
Eur. Respir. J.
Evidence for excessive bronchial inflammation during an acute exacerbation of COPD in patients with α-1-antitrypsin deficiency
Am. J. Respir. Crit. Care Med.
Proteinase 3 activity in sputum from subjects with α-1-antitrypsin deficiency and COPD
Eur. Respir. J.
Exacerbations in α-1-antitrypsin deficiency
Eur. Respir. J.
Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in α-1 antitrypsin-deficient COPD
Int. J. Chron. Obstruct. Pulmon. Dis.
Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency
Eur. Respir. J.
The effect of augmentation therapy on bronchial inflammation in α1-antitrypsin deficiency
Am. J. Respir. Crit. Care Med.
The natural history of liver disease in α1-antitrypsin deficient children
Acta Paediatr. Scand.
Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease
Am. J. Respir. Crit. Care Med.
Liver disease in α-1 antitrypsin deficiency: current understanding and future therapy
COPD
Panniculitis associated with severe α1-antitrypsin deficiency. Treatment and review of the literature
Arch. Dermatol.
Cited by (64)
Pulmonary fibroelastosis - A review
2023, Matrix BiologyNovel formulations and drug delivery systems to administer biological solids
2021, Advanced Drug Delivery ReviewsAlpha 1 Antitrypsin
2021, Encyclopedia of Respiratory Medicine, Second EditionDelivery of genome-editing biomacromolecules for treatment of lung genetic disorders
2021, Advanced Drug Delivery ReviewsCitation Excerpt :Patients with AATD can also progress into COPD, which is often triggered by interactions between environmental and genetic factors [61]. Currently, the intravenous infusion of purified human AAT protein is the gold standard of therapeutic option for the prevention of emphysema patients with AATD [62–64]. The protective action of augmentation therapy is very effective in improving wild-type AAT circulating levels, and lung function can be further improved via weekly or biweekly intravenous infusion of AAT protein [64].
An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana
2018, Free Radical Biology and Medicine